Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea ( 43 [ 66 % ] of 652 vs 17 [ 26 % ] of 655 ) , reversible increases in alanine aminotransferase ( 51 [ 78 % ] vs six [ 09 % ] ) , and reversible increases in aspartate aminotransferase ( 22 [ 34 % ] vs three [ 05 % ] ) .